Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inhibikase Therapeutics (IKT) Income from Continuing Operations (2020 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Income from Continuing Operations for 6 consecutive years, with 12768373.0 as the latest value for Q3 2025.

  • On a quarterly basis, Income from Continuing Operations fell 119.11% to 12768373.0 in Q3 2025 year-over-year; TTM through Sep 2025 was 51127357.0, a 154.82% decrease, with the full-year FY2024 number at 28589068.0, down 42.31% from a year prior.
  • Income from Continuing Operations was 12768373.0 for Q3 2025 at Inhibikase Therapeutics, down from 10832278.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 2636179.0 in Q2 2021 to a low of 14598006.0 in Q1 2025.
  • A 5-year average of 6303876.84 and a median of 4768876.0 in 2023 define the central range for Income from Continuing Operations.
  • Peak YoY movement for Income from Continuing Operations: plummeted 566.75% in 2021, then grew 18.57% in 2024.
  • Inhibikase Therapeutics' Income from Continuing Operations stood at 5041619.0 in 2021, then rose by 14.02% to 4334974.0 in 2022, then decreased by 1.58% to 4403566.0 in 2023, then tumbled by 193.6% to 12928700.0 in 2024, then increased by 1.24% to 12768373.0 in 2025.
  • Per Business Quant, the three most recent readings for IKT's Income from Continuing Operations are 12768373.0 (Q3 2025), 10832278.0 (Q2 2025), and 14598006.0 (Q1 2025).